We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
-6.53%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$22.9M
(+6.3%)
Cap. Flow
+$49.3M
Cap. Flow
% of AUM
12.82%
Top 10 Holdings %
Top 10 Hldgs %
35.81%
Holding
89
New
18
Increased
39
Reduced
11
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$9.14M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$7.54M |
| 3 |
Guardant Health
GH
|
+$6.84M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$6.76M |
| 5 |
Merck
MRK
|
+$5.91M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$13.7M |
| 2 |
Abbott
ABT
|
+$9.85M |
| 3 |
Fate Therapeutics
FATE
|
+$7.61M |
| 4 |
AbbVie
ABBV
|
+$6.77M |
| 5 |
Labcorp
LH
|
+$6.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITOS
51
DELISTED
iTeos Therapeutics
ITOS
| $2.73M | 0.71% |
85,000
+35,000
| +70% | +$1.27M |
|
52
Inspire Medical Systems
INSP
$1.71B
| $2.57M | 0.67% |
+10,000
| New | +$2.29M |
|
|
ITCI
53
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.45M | 0.64% |
+40,000
| New | +$2.08M |
|
|
FOLD
54
DELISTED
Amicus Therapeutics
FOLD
| $2.12M | 0.55% |
224,000
+49,000
| +28% | +$459K |
|
|
ICPT
55
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.03M | 0.53% |
125,000
+50,000
| +67% | +$783K |
|
|
APLS
56
DELISTED
Apellis Pharmaceuticals
APLS
| $2.02M | 0.53% |
39,769
-80,231
| -67% | -$3.54M |
|
57
Kiniksa Pharmaceuticals
KNSA
$6.07B
| $1.7M | 0.44% |
171,000
+31,000
| +22% | +$328K |
|
58
PTC Therapeutics
PTCT
$6.15B
| $1.57M | 0.41% |
42,000
-3,000
| -7% | -$116K |
|
59
Doximity
DOCS
$4.65B
| $1.56M | 0.41% |
+30,000
| New | +$1.51M |
|
60
Lifestance Health
LFST
$4.39B
| $1.52M | 0.39% |
+150,000
| New | +$1.32M |
|
61
Incyte
INCY
$24.5B
| $1.43M | 0.37% |
18,000
-12,000
| -40% | -$873K |
|
|
RETA
62
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.15M | 0.3% |
35,000
-68,000
| -66% | -$2.02M |
|
63
Precision BioSciences
DTIL
$207M
| $1.08M | 0.28% |
11,667
+5,834
| +100% | +$793K |
|
64
PMV Pharmaceuticals
PMVP
$69.3M
| $1.04M | 0.27% |
+50,000
| New | +$882K |
|
|
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $962K | 0.25% |
+30,000
| New | +$861K |
|
|
FMTX
66
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $837K | 0.22% |
90,000
+15,000
| +20% | +$160K |
|
67
Denali Therapeutics
DNLI
$3.95B
| $836K | 0.22% |
26,000
-74,000
| -74% | -$2.55M |
|
68
Dianthus Therapeutics
DNTH
$6.07B
| $583K | 0.15% |
12,563
+6,938
| +123% | +$379K |
|
|
CMRX
69
DELISTED
Chimerix, Inc.
CMRX
| $545K | 0.14% |
119,000
+9,000
| +8% | +$50.2K |
|
70
Avalo Therapeutics
AVTX
$1.04B
| $507K | 0.13% |
243
-321
| -57% | -$806K |
|
|
LBPH
71
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $254K | 0.07% |
47,600
+17,600
| +59% | +$83.5K |
|
|
72
AbbVie
ABBV
$442B
| – | – |
-50,000
| Closed | -$6.77M |
|
|
73
Abbott
ABT
$190B
| – | – |
-70,000
| Closed | -$9.85M |
|
74
Alnylam Pharmaceuticals
ALNY
$29.6B
| – | – |
-20,000
| Closed | -$3.39M |
|
|
AMRN
75
Amarin Corp
AMRN
$296M
| – | – |
-10,000
| Closed | -$674K |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Integral Health Asset Management held 89 positions worth $384M, up 6.3% from $361M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Integral Health Asset Management deployed $49.3M of net new capital in Q1 2022, opening 18 new positions and adding to 39 existing holdings. Its largest new stake was CRISPR Therapeutics: 120,000 shares worth $7.53M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.
On the sell side, the largest reduction was Centene, an estimated $6.15M trimmed.
- Integral Health Asset Management's largest Q1 2022 buy was CRISPR Therapeutics: 120,000 shares worth $7.53M.
- Integral Health Asset Management added most to Elevance Health in Q1 2022, an estimated $9.14M increase.
- Integral Health Asset Management's biggest Q1 2022 reduction was Centene, cutting an estimated $6.15M.
- Integral Health Asset Management fully exited McKesson in Q1 2022, selling an estimated $13.7M.
- Integral Health Asset Management's ten largest holdings make up 36% of its $384M portfolio in Q1 2022.
- Integral Health Asset Management opened 18 new positions and closed 18 in Q1 2022.
- Integral Health Asset Management's portfolio value rose 6.3% quarter-over-quarter to $384M.
Based on Integral Health Asset Management's 13F filing for Q1 2022, filed 12 May 2022.